SEC Form 4 · accession 0001140361-17-041866
Emergent BioSolutions Inc. · EBS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George A Joulwan
Director
Period of report
Nov 7, 2017
Accepted (ET)
Nov 9, 2017 · 4:57 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001367644
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 7, 2017 | M | 3,946 | $15.97 | A | 34,323 | D | |
| Common StockF1 | Nov 7, 2017 | S | 3,946 | $41.24 | D | 30,377 | D | |
| Common Stock | Nov 7, 2017 | M | 10,305 | $18.64 | A | 40,682 | D | |
| Common StockF1 | Nov 7, 2017 | S | 10,305 | $41.24 | D | 30,377 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to buy)F2,F3 | $15.97 | Nov 7, 2017 | M | 3,946 | D | — | Jul 17, 2020 | Common Stock | 3,946 | 0 | D |
| Employee Stock Option (Right to buy)F2,F3 | $18.64 | Nov 7, 2017 | M | 10,305 | D | — | May 22, 2021 | Common Stock | 10,305 | 0 | D |
Explanation of responses
- F1The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.45, inclusive.
- F2Consists of an option granted under the company's stock incentive plan as amended and restated.
- F3The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.